A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Capecitabine is an oral fluoropyrimidine that has been shown to be effective in the treatment
of metastatic gastric and colorectal cancer patients. On the basis of capecitabine-based
chemotherapy which is accepted as a standard regimen in gastric cancer, we will perform the
phase I/II study with all-oral regimen of RAD001 with capecitabine for these refractory
gastric cancer patients.